- Vertex Pharmaceuticals (NASDAQ:VRTX): Q3 Non-GAAP EPS of $2.64 beats by $0.31; GAAP EPS of $2.53 beats by $0.55.
- Revenue of $1.54B (+62.1% Y/Y) beats by $60M.
- Cash, cash equivalents and marketable securities as of September 30, 2020 were $6.2B.
- Combined GAAP R&D and SG&A expenses decreased compared to the Q3 2019 due to a decrease in collaboration payments.
- Press Release
- https://seekingalpha.com/news/3628553-vertex-pharmaceuticals-eps-beats-0_31-beats-on-revenue
Thursday, October 29, 2020
Vertex Pharmaceuticals EPS beats by $0.31, beats on revenue
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.